Alkermes vs Axsome Therapeutics
ALKS and AXSM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALKS and AXSM compare
Alkermes and Axsome Therapeutics are about the same size, with market caps of $7.6B and $7.6B.
Axsome Therapeutics grew revenue faster over the last twelve months (56.9% versus 10.8% for Alkermes).
Alkermes keeps more of each dollar of sales as profit, with a net margin of 4.0% compared with −24.7% at Axsome Therapeutics.
Axsome Therapeutics scores higher on the StockData Score (8 against 5 for Alkermes), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALKS | AXSM |
|---|---|---|
| Size and price | ||
| Market cap | $7.6B | $7.6B |
| Share price | $45.34 | $144.43 |
| Change, 1 year | 44.2% | 8.3% |
| Change, 5 years | 49.5% | 259% |
| Beta (5Y) | 0.43 | 0.48 |
| Employees | 2,050 | 500 |
| StockData Score | ||
| Total score | 5 | 8 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 2 | 2 |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 119× | – |
| P/S | 4.6× (better) | 9.7× |
| P/B | 4.2× (better) | 90.8× |
| EV/EBITDA | 47.3× | – |
| P/FCF | 34.3× | – |
| FCF yield | 2.9% (better) | −0.95% |
| Fair value | $19.85 | – |
| Margin of safety | −128% | – |
| Growth | ||
| Revenue growth (TTM) | 10.8% | 56.9% (better) |
| Revenue growth, 5Y average | 7.3% | – |
| Net income growth (TTM) | −81.0% | – |
| EPS growth (TTM) | −81.7% | – |
| Profitability | ||
| Gross margin | 84.6% | 93.2% (better) |
| Operating margin | 7.0% (better) | −24.0% |
| Net margin | 4.0% (better) | −24.7% |
| FCF margin | 13.3% (better) | −9.3% |
| Return on equity | 3.9% (better) | −245% |
| Return on invested capital | 4.9% | – |
| Financial health | ||
| Debt / equity | 0.83 (better) | 2.26 |
| Net debt / EBITDA | 4.73 | – |
| Interest coverage | 2.0× | – |
| Current ratio | 2.30 (better) | 1.43 |
| Altman Z-score | 2.21 | 4.60 (better) |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Buyback yield | – | −0.47% |
| Shareholder yield | 0.00% (better) | −0.47% |
| Ownership | ||
| Held by institutions | 106% | 73.8% |
| Held by insiders | 1.6% | 15.2% |
| Insider net buying, 12 months | −$10.2M (better) | −$134M |
| Short interest, % of float | 10.8% | 7.4% |
Go deeper
- ALKS stock overview
- ALKS income statement
- ALKS valuation and score
- AXSM stock overview
- AXSM income statement
- AXSM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.